Table 2.

Efficacy of microRNAs in the differential diagnosis of pancreatic cancer from healthy participants

Study	MicroRNAs	source	Diagnostic power
			AUC		Sensitivity		Specificity		Accuracy
			Training	Validation	Training	Validation	Training	Validation	Training	Validation
Schultz et al	Panel I	Blood	0.86	0.83	0.85	0.85	0.64	0.48	0.74	0.72
	Panel I + C*	Blood	0.93	0.94	0.85	0.85	0.95	0.98	0.90	0.89
	Panel II	Blood	0.93	0.82	0.85	0.85	0.85	0.55	0.85	0.75
	Panel II + C*	Blood	0.97	0.93	0.85	0.85	0.98	0.90	0.92	0.86
Zou et al	Six‐miRNA panel	Serum	0.910	0.978	0.953	0.933	0.767	0.96
Yu et al	miR-25	Serum		0.939		0.825		0.9364		0.8895
	miR-25 + C*	Serum		0.985		0.975		0.9011		0.9895
Debernardi et al	miR-143	Urine		0.862		0.833		0.885
	miR-143 + miR-30	Urine		0.923		0.833		0.962
Yang et al	miR-21 + miR-155	Stool		0.8111		0.9333		0.6667
	miR-21 + miR-155 + miR-216	Stool		0.8667		0.8333		0.8333
Machida et al	miR-1246	Salivary		0.814		0.667		1.0
	miR-4644	Salivary		0.763		0.750		0.769
	miR-1246 + 4644	Salivary		0.833		0.833		0.923

C* = CA19-9. Panel I is composed of miR-145, miR-150, miR-223, miR-636; Panel II is composed of miR-26b, miR-34a, miR-122, miR-126, miR-145, miR-150, miR-223, miR-505, miR-636, miR-885-5p; six‐miRNA panel contains let‐7b‐5p, miR‐192‐5p, miR‐19a‐3p, miR‐19b‐3p, miR‐223‐3p, and miR‐253p